Thank you, Anette. And so, I first wanted to go through the history of our Biologics License Application, also called BLA, for our biosimilar candidate under the development name Xlucane. It was submitted in April last year, and the FDA took a so-called filing decision in June 2023, and the review process of the BLA was then started. Um, and a basis for that, that is to say, a goal date or a decision date was set to April 21st, 2024. So that is the date, uh, when the FDA, according to the dictated process, needs to take action, a decision either to approve the application or to, um, postpone the date or issue a so-called Complete Response Letter we had during the review process. Um, as is dictated by the process, both mid-cycle and late-cycle review meetings with the FDA in October and January 2024, respectively, uh, where no major issues were at that point in time. Uh identified um, as is part of um, review processes, uh, for approval in the US, um, you typically conduct so-called pre-approval inspections at the manufacturing sites involved and proposed to produce the product for commercial supply to the US that took place, uh, even for this review process in January and February this year, respectively. Um, and, uh. In those inspections. There were observations from the FDA, which you then typically have a three-week response time on, and the respective sites responded to the FDA within that timeframe. And we also received, of course, numerous different information requests from the FDA on the application itself throughout the whole review process, which were responded to in time. So, um. Friday evening US time, that is to say, 19th of April. Um, we received a so-called Complete Response Letter from the FDA. Um, and it contained, uh, two main, um, deficiencies in relation to the application, which, according to the FDA, needed to be resolved in order for them to be able to approve, uh, the application. The first one was related to, um, the so-called reference standard to be used for release of the product to the US market. And I'm here going to hand over to David to elaborate a little bit further on this specific, uh, deficiency identified or stated by the FDA.